Turesson Ingemar, Bjorkholm Magnus, Blimark Cecilie Hveding, Kristinsson Sigurdur, Velez Ramon, Landgren Ola
Department of Haematology, Skane University Hospital, Malmo, Sweden.
Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Eur J Haematol. 2018 Apr 20. doi: 10.1111/ejh.13083.
The incidence of multiple myeloma is characterized by a steep increase with advancing age. Dramatic improvements in survival have been reported in clinical trials; however, elderly patients are generally underrepresented in these. The aims of this study are to review patterns of incidence and survival in multiple myeloma in the general population. We searched PubMed for population-based studies on trends in incidence and survival published between January 1, 2000 and June 30, 2017 and based on regional or national cancer registries and report the following results of the review. The age-adjusted incidence of multiple myeloma has increased during the second half of the twentieth century in some countries but remained stable in areas with high case ascertainment and access to universal medical care. The crude incidence is increasing globally due to an aging population. Survival rates have improved, and 5-year relative survival rates are now around 50% and over 60% in patients 65-70 years or younger. Preliminary data suggest a 3-fold increase in the prevalence of multiple myeloma. We conclude that the number of multiple myeloma patients is increasing in the general population due to (i) aging populations and (ii) more patients living longer due to modern drugs.
多发性骨髓瘤的发病率随年龄增长呈急剧上升趋势。临床试验报告显示生存率有显著提高；然而，老年患者在这些试验中的代表性普遍不足。本研究的目的是回顾普通人群中多发性骨髓瘤的发病率和生存模式。我们在PubMed上搜索了2000年1月1日至2017年6月30日期间基于区域或国家癌症登记处发表的关于发病率和生存趋势的人群研究，并报告了以下综述结果。在二十世纪后半叶，一些国家多发性骨髓瘤的年龄调整发病率有所上升，但在病例确诊率高且能获得全民医疗服务的地区保持稳定。由于人口老龄化，全球粗发病率正在上升。生存率有所提高，目前65至70岁及以下患者的5年相对生存率约为50%，60%以上。初步数据表明多发性骨髓瘤的患病率增加了两倍。我们得出结论，普通人群中多发性骨髓瘤患者数量正在增加，原因如下：（i）人口老龄化；（ii）由于现代药物，更多患者寿命延长。
